首页|外用红色诺卡氏菌细胞壁骨架治疗宫颈高危型HPV持续感染的临床疗效

外用红色诺卡氏菌细胞壁骨架治疗宫颈高危型HPV持续感染的临床疗效

扫码查看
目的 外用红色诺卡氏菌细胞壁骨架(简称:红卡,Nr-CWS)治疗宫颈高危型人乳头瘤病毒(HPV)持续感染的临床效果。方法 选择 100 例高危型HPV持续感染患者,随机分为对照组(50 例)及研究组(50 例)。对照组采用干扰素治疗,研究组选用红卡治疗。比较两组患者的HPV治疗效果,外周血淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+)水平,阴道灌洗液中免疫因子[白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、γ干扰素(IFN-γ)]水平,不良反应发生情况。结果 研究组总有效率 96%高于对照组的 60%(P<0。05)。治疗后,两组外周血CD4+、CD4+/CD8+高于本组治疗前,且研究组CD4+(40。04±2。15)%、CD4+/CD8+(1。30±0。16)较对照组的(36。46±3。61)%、(1。18±0。16)高(P<0。05)。两组CD8+治疗前后组间组内比较,差异无统计学意义(P>0。05)。治疗后,两组阴道灌洗液中IL-2、IFN-γ、TNF-α高于本组治疗前,IL-4低于本组治疗前,且研究组IL-2(97。24±4。13)ng/L、TNF-α(36。68±3。14)ng/L、IFN-γ(32。35±2。14)ng/L较对照组的(92。15±5。04)、(33。23±2。21)、(28。78±2。11)ng/L高,IL-4(12。79±1。88)ng/L较对照组的(14。52±2。13)ng/L低(P<0。05)。两组IL-6、IL-10 治疗前后组间组内比较,差异无统计学意义(P>0。05)。两组患者接受治疗过程中没有出现任何严重的不良反应或不适感。结论 使用红卡治疗对改善宫颈高危型HPV持续感染患者的转阴率、治愈率有积极作用,安全性高,能提高生存质量,值得推广。
Clinical efficacy of topical Nocardia rubra cell-wall skeleton in the treatment of persistent high-risk HPV infection of the cervix
Objective To explore the clinical effect of topical Nocardia rubra cell-wall skeleton(Nr-CWS)in the treatment of persistent high-risk human papillomavirus(HPV)infection of the cervix.Methods 100 patients with persistent high-risk HPV infection were randomly divided into a control group(50 cases)and a study group(50 cases).The control group was treated with interferon,and the study group was treated with Nr-CWS.Patients in both groups were compared in terms of HPV treatment effect and peripheral blood lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)levels,levels of immune factors[interleukin-2(IL-2),interleukin-4(IL-4),interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)]in vaginal lavage fluid,and the occurrence of adverse reactions.Results The total effective rate of 96%in the study group was higher than 60%in the control group(P<0.05).After treatment,the peripheral blood CD4+and CD4+/CD8+in both groups were higher than those before treatment in this group;the study group had CD4+of(40.04±2.15)%and CD4+/CD8+of(1.30±0.16),which were higher than(36.46±3.61)%and(1.18±0.16)in the control group(P<0.05).Before and after treatment,there was no significant difference in CD8+between and within the two groups(P>0.05).After treatment,the levels of IL-2,IFN-γ and TNF-α in both groups were higher than those before treatment,while the level of IL-4 was lower than that before treatment;the study group had IL-2 of(97.24±4.13)ng/L,TNF-α of(36.68±3.14)ng/L and IFN-γ of(32.35±2.14)ng/L,which were higher than(92.15±5.04),(33.23±2.21)and(28.78±2.11)ng/L in the control group;IL-4 of(12.79±1.88)ng/L in the study group was lower than(14.52±2.13)ng/L in the control group(P<0.05).Before and after treatment,there was no significant difference in IL-6 and IL-10 between and within the two groups(P>0.05).No serious adverse reactions or discomfort occurred during treatment in both groups.Conclusion The use of Nr-CWS has a positive effect on improving the negative-conversion rate and cure rate of patients with persistent high-risk HPV infection of the cervix,and it is safe and can improve the quality of life,which is worth promoting.

Human papillomavirusCervical cancerTopical Nocardia rubra cell-wall skeletonImmune cellsImmune factors

刘美玲

展开 >

361000 厦门弘爱妇产医院妇科

人乳头瘤病毒 宫颈癌 外用红色诺卡氏菌细胞壁骨架 免疫细胞 免疫因子

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(19)